Targinact--opioid pain relief without constipation?
Targinact (Napp Pharmaceuticals Ltd) is a modified-release combination product containing the strong opioid oxycodone plus the opioid antagonist naloxone. It is licensed for "severe pain, which can be adequately managed only with opioid analgesics".1 The summary of product characteristics (SPC) states that "naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut". Advertising for the product claims "better pain relief", "superior GI [gastrointestinal] tolerability" and "improved quality of life" "compared to previous treatment in a clinical practice study (n=7836)". Here we consider whether Targinact offers advantages over using strong opioids plus laxatives where required.
D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000009:adverse effects; D003248:Constipation / Q000139:chemically induced / Q000517:prevention & control; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D005500:Follow-Up Studies; D006801:Humans; D009270:Naloxone / Q000008:administration & dosage / Q000009:adverse effects; D010098:Oxycodone / Q000008:administration & dosage / Q000009:adverse effects; D010146:Pain / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic
D000701:Analgesics, Opioid; D003692:Delayed-Action Preparations; D004338:Drug Combinations; C557247:oxycodone naloxone combination; D009270:Naloxone; D010098:Oxycodone